Legality of CBD in Slovakia: When Will It Be Legal

04/05/2020 Author: Vendula 8 min read

CBD Legality in Slovakia

For many years, the topic of cannabis, including medical cannabis, was a major taboo in Slovakia. However, last year the Slovak government decided to make a radical change.

Legal status of cannabis in the European Union (as of 25 September 2026)

The EU has no single cannabis law: it sets a common framework for hemp farming, trade and drug trafficking, while recreational use is regulated by each Member State.
CBD lawfully produced in one Member State may in principle be sold in another; a national ban is allowed only if it is suitable to protect public health and does not go beyond what is necessary. The Court held that such CBD is not a narcotic drug under the 1961 Single Convention (Articles 34 and 36 TFEU, Case C-663/18 Kanavape, paras 76 and 96).
Industrial hemp qualifies for CAP direct payments only if the THC content of the variety does not exceed 0.3 % (Art. 4(4) Regulation (EU) 2021/2115); THC control methods are set by the Commission (Art. 60(4)(a) Regulation (EU) 2021/2116).
Member States may restrict how hemp is grown, for example ban indoor hydroponic cultivation, if the restriction is suitable and proportionate for protecting public health (Case C-793/22 Biohemp Concept, 4 October 2024).
Member States must make intentional unlawful cultivation of cannabis plants and drug trafficking a criminal offence (Art. 2(1)(b) Framework Decision 2004/757/JHA, as quoted in Case C-271/23).
Rules on recreational cannabis differ widely: Germany allows adults to possess up to 25 g in public, 50 g at home and three plants (§ 3 and § 9 KCanG), while in Czechia personal use becomes a criminal offence only above 5 plants, 200 g at home or 50 g elsewhere, and plants with up to 1 % THC are excluded (§ 285 Czech Criminal Code).

“Články 34 a 36 SFEU musí být vykládány v tom smyslu, že brání vnitrostátní právní úpravě, která zakazuje uvádět na trh CBD, který je legálně vyprodukován v jiném členském státě, v případě, že je extrahován z celé rostliny cannabis sativa, a nikoli pouze z jejích vláken a semen, ledaže je tato právní úprava s to zaručit naplnění cíle ochrany veřejného zdraví a nepřekračuje meze toho, co je k dosažení tohoto cíle nezbytné.”
[Translation: “Articles 34 and 36 TFEU must be interpreted as precluding national legislation which prohibits the marketing of CBD lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds, unless that legislation is appropriate for securing the attainment of the objective of protecting public health and does not go beyond what is necessary for that purpose.”]
Court of Justice of the European Union, 19 November 2020, Case C-663/18 (Kanavape)

This overview is based on legislation and case law in the legal database Europaius. It is not legal advice.

The Legal Status of CBD in Slovakia: A Complex Path

For years, Slovakia was a special case in the European regulatory landscape for therapeutic hemp. While most European Union countries had already recognized the legality of Cannabidiol (CBD), this Central European country maintained a restrictive stance that classified this non-psychoactive molecule as a controlled substance.

On August 21, 2019, the turning point seemed to have arrived: The Slovak government announced its decision to remove Cannabidiol from the list of narcotic and psychotropic substances. This decision was meant to align Slovakia with the more progressive European policies regarding industrial hemp and its derivatives.

The Chemical and Biological Properties of Cannabidiol

To better understand the legal question, it is important to consider the properties of Cannabidiol as a chemical compound. CBD is primarily extracted from industrial hemp varieties, genetics characterized by a high content of this cannabinoid and THC concentrations below the European limit of 0.2%.

The therapeutic properties of CBD have been the subject of numerous scientific studies that have demonstrated its potential as a non-psychoactive compound. Unlike THC, Cannabidiol does not induce perception-altering effects but rather exhibits a high safety profile, which led the World Health Organization to recognize its therapeutic value.

From a terpene chemistry perspective, CBD-rich varieties often display complex aromatic profiles, with notes ranging from herbal and floral to earthier and spicier tones. These aromatic compounds, together with the cannabinoids, contribute to what is known as the "entourage effect" – a synergistic phenomenon among the various components of the plant.

Applications of Industrial Hemp

The versatility of industrial hemp goes far beyond the extraction of cannabinoids. Historically used for producing textile fibers and paper, this plant now finds applications in the production of bioplastics, eco-friendly building materials, and food products.

Hemp seeds, for example, are a valuable source of plant protein and essential fatty acids. These food products derived from hemp are appreciated for their complete nutritional profile and good digestibility.

Legislative Development: Promise and Reality

The 2011 legislative amendment placed Cannabidiol on the list of second-degree psychotropic substances, paradoxically equating it with significantly more dangerous synthetic drugs. This classification made all products containing CBD illegal, including oils, tinctures, and dietary supplements that were freely sold in other European countries.

The Slovak government's 2019 decision seemed to promise a radical change of course. Proponents of the reform justified the proposal based on international scientific findings and WHO positions confirming that CBD is a safe substance with good therapeutic potential.

The Role of Sativex in the Legal Discussion

A crucial aspect of the discussion concerned the approval of the medication Sativex, used to treat Multiple Sclerosis. This pharmaceutical, containing both CBD and THC in controlled ratios, required a legislative amendment to be legally distributed in the country.

The legalization of therapeutic CBD thus represented not only a matter of aligning with European regulations but also a necessary step to ensure Slovak patients access to innovative therapies that were already available in the rest of Europe.

Future Perspectives and Scientific Considerations

Despite the expectations, the implementation of the reform faced significant delays. The new legal framework, which was to take effect on January 1, 2020, primarily resulted in an expansion of the list of controlled substances without the hoped-for removal of CBD.

From a scientific perspective, cannabinoid research continues to provide interesting insights. Studies on the human endocannabinoid system have shown how these compounds interact with specific receptors in our organism, opening new perspectives for targeted therapeutic applications.

The question of dependence, frequently raised in legal debates, has been thoroughly examined for CBD. Research has confirmed that this cannabinoid exhibits no dependence potential and thus differs markedly from other psychoactive substances.

The European Context and Collector Genetics

While Slovakia maintained its restrictive stance, the industrial hemp sector continued to develop in the rest of Europe. Collector genetics represent an important heritage for preserving the genetic diversity of hemp, by maintaining traditional varieties and developing new cannabinoid and terpene profiles.

For enthusiasts and collectors of genetics, understanding the chemical profiles of different varieties remains a fascinating aspect. Each cultivar exhibits unique characteristics regarding cannabinoid production, terpene expression, and environmental resistance.

The situation in Slovakia demonstrates how national policies can significantly influence the development of this sector, from scientific research to the availability of products for consumers. The harmonization of European regulations remains an important goal to ensure the free movement of safe and regulated products within the common market.